00
002603.SHE Shijiazhuang Yiling Pharmaceutical Co Ltd
- Market cap
- CNY 25.9B
- P/E
- 18.7x
- P/B
- 2.30x
- ROE
- 13.0%
- Dividend yield
- 1.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002603.SHE undervalued?
Graham number002603.SHE trades 38.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shijiazhuang Yiling Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shijiazhuang Yiling Pharmaceutical Co Ltd yet.
Shijiazhuang Yiling Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and personal protective equipment products; and TCM formula granules. Shijiazhuang Yilin…
Full company profileShijiazhuang Yiling Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shijiazhuang Yiling Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.85B | 4.08B | 4.81B | 5.83B | 8.78B | 10.1B | 12.5B | 10.3B | 6.51B | 7.83B | 7.96B |
| Gross Profit | 2.57B | 2.78B | 3.18B | 3.72B | 5.66B | 6.42B | 7.98B | 5.88B | 3.03B | 5.03B | 5.10B |
| Operating Income | 613M | 650M | 719M | 710M | 1.44B | 1.57B | 2.83B | 1.78B | -689M | 1.78B | 1.78B |
| EBITDA | 837M | 843M | 931M | 911M | 1.69B | 1.87B | 3.29B | 2.15B | -236M | 2.22B | 1.76B |
| Net Income | 533M | 541M | 599M | 607M | 1.22B | 1.34B | 2.36B | 1.35B | -725M | 1.29B | 1.46B |
| EPS | 0.34 | 0.32 | 0.36 | 0.36 | 0.73 | 0.80 | 1.41 | 0.81 | -0.43 | 0.77 | 0.87 |
| Balance Sheet | |||||||||||
| Total Assets | 6.26B | 7.89B | 8.56B | 9.07B | 11.5B | 12.9B | 16.3B | 17.0B | 13.3B | 13.7B | 14.2B |
| Total Liabilities | 925M | 776M | 994M | 1.12B | 2.58B | 3.83B | 5.41B | 5.54B | 3.12B | 2.69B | 2.91B |
| Shareholders' Equity | 5.32B | 7.11B | 7.56B | 7.94B | 8.92B | 9.07B | 10.9B | 11.4B | 10.2B | 11.0B | 11.2B |
| Cash & Short-term Investments | 647M | 1.67B | 1.48B | 1.03B | 1.55B | 1.05B | 2.42B | 1.15B | 853M | 1.10B | 702M |
| Total Debt | 100M | - | - | 50.1M | 281M | 1.01B | 715M | 1.21B | 18.2M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 641M | 115M | 72.4M | 68.9M | 1.59B | 529M | 3.49B | 155M | 611M | 1.78B | - |
| Capital Expenditure | 373M | 180M | 187M | 454M | 1.14B | 674M | 214M | 311M | 290M | 246M | 184M |
| Free Cash Flow | 259M | -65.7M | -115M | -386M | 441M | -145M | 3.27B | -155M | 321M | 1.53B | 1.96B |
| Ratios | |||||||||||
| ROE | 10.0% | 7.6% | 7.9% | 7.6% | 13.7% | 14.8% | 21.6% | 11.8% | -7.1% | 11.7% | 13.0% |
| ROA | 8.5% | 6.9% | 7.0% | 6.7% | 10.6% | 10.4% | 14.5% | 8.0% | -5.4% | 9.4% | 10.3% |
| Net Profit Margin | 13.8% | 13.2% | 12.4% | 10.4% | 13.9% | 13.3% | 18.9% | 13.1% | -11.1% | 16.4% | 18.4% |
| Debt to Equity | 0.02x | - | - | 0.01x | 0.03x | 0.11x | 0.07x | 0.11x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shijiazhuang Yiling Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.94%
- Forward dividend
- 0.80 CNY
- Payout ratio
- 39.0%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 501M | 0.30 | 39.0% |
| 2024 | CNY 375M | 0.22 | - |
| 2023 | CNY 835M | 0.50 | 61.8% |
| 2022 | CNY 283M | 0.17 | 12.0% |
| 2021 | CNY 1.19B | 0.71 | 88.8% |
| 2020 | CNY 239M | 0.14 | 19.6% |
| 2019 | CNY 120M | 0.07 | 19.7% |
| 2018 | CNY 121M | 0.07 | 20.1% |
| 2017 | CNY 103M | 0.06 | 19.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 7, 2021.
Who owns Shijiazhuang Yiling Pharmaceutical Co Ltd
- Insiders 55.94%
- Institutions 4.95%
- Public & others 39.11%
- Shares outstanding 1.67B
- Free float 734M
Shijiazhuang Yiling Pharmaceutical Co Ltd company profile
- Company name
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Ticker
- 002603.SHE
- ISIN
- CNE1000015S0
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 28, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 11,343
- Fiscal year end
- December
- Address
- No. 238 Tianshan Street, Shijiazhuang, China, 050035
- Phone
- 86 40 0789 8989
- Website
- yiling.cn
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and personal protective equipment products; and TCM formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Shijiazhuang Yiling Pharmaceutical Co Ltd management
8- Mr. Xiang Jun WuChairman & GM · born 1975
- Mr. Chen Guang LiCFO & Director · born 1973
- Ms. Wei WangDeputy GM & Director of Administrative Center · born 1970
- Mr. Keyuan ZhangDeputy GM, GM of the Marketing & Non-Independent Director · born 1967
- Mr. Wei Dong XuExecutive Deputy Director of the Human Resources Center & Director · born 1968
- Dr. Rui WuSecretary of the Board & Non-Independent Director · born 1980
- Mr. Xiaolin ZhouDeputy GM & Director of the Supply Center · born 1970
- Ms. Liqin CaiAccounting Supervisor